Seeking Alpha

Organovo +16% even as report says 3D printing of organs could be banned

  • Shares of Organovo (ONVO +16%) continue to surge despite an IBTimes UK report that says research firm Gartner predicts 3D bioprinted human organs will soon become a reality, which could ignite calls to ban the technology.
  • The Gartner report raises moral and ethical questions about whether organs should be printed using non-human cells or a mix of human and non-human cells, and whether there is a difference between this and genetically modified food crops.
  • ONVO, deeply involved in such research, said this morning it has performed its first 3D Liver tissue delivery and expects to begin the commercial launch of its 3D Liver tissue product before year-end.
Comments (16)
  • Stan The Man
    , contributor
    Comments (142) | Send Message
    Why is it relevant in this blurb to mention that there "may be" calls to ban 3D organ printing, if and when human organs are shown to be 3D printable?


    ONVO is just at the beginning of an effort to print 3D human liver tissue to be used for researching of drugs and similar applications. That's where their current commercial focus is. That's the product they are just starting to deliver.
    29 Jan, 11:09 AM Reply Like
  • Jeffjacobjames
    , contributor
    Comments (437) | Send Message
    What a BOGUS opinion!! Some short put this out to slow today's HUGE news! Stay long and strong with ONVO!
    29 Jan, 11:15 AM Reply Like
  • alfredocamera
    , contributor
    Comments (16) | Send Message
    as soon a good news is published someone try to push down the share prize down with those insignificant news
    29 Jan, 11:34 AM Reply Like
  • Halios
    , contributor
    Comment (1) | Send Message
    Right... because governments will really ban a technology that can fill the massive demand for organs around the world (and this probably includes the lawmakers themselves when they get really old and need new livers/bladders/etc).


    Whoever wrote said Gartner report is lacking in long-term thinking.
    29 Jan, 12:34 PM Reply Like
  • flyer777
    , contributor
    Comments (11) | Send Message
    Keith Murphy is scheduled to be on Fox Business with Mellisa Francis today at 5:00 EST.
    Shorts will say and do everything to keep ONVO down. Short interest rose from 8.6 million to 11.2 million shares.
    29 Jan, 12:55 PM Reply Like
  • deckmaker12
    , contributor
    Comments (45) | Send Message
    Yep cannot wait for this garbage to stop. When the leading guy in the field is in the company that is developing it and he is doing good the shorters are coming out to do everything to destroy it. Where is that guy that kept tossing numbers around about inside trading?? Haven't heard from him yet.
    29 Jan, 01:14 PM Reply Like
  • Green Eagle
    , contributor
    Comments (5) | Send Message
    Banning manufactured oragns is absurd when you consider the facts:
    29 Jan, 01:34 PM Reply Like
  • Rustbelt Bill
    , contributor
    Comments (3) | Send Message
    I hope the shorts keep it up - I have some cash coming soon and I'd like the price to stay low for just a little longer...
    29 Jan, 01:34 PM Reply Like
  • Dr. Know
    , contributor
    Comments (12) | Send Message
    This update is highly suspect. There have been no new calls to ban the technology today; why include that little gem?
    29 Jan, 01:34 PM Reply Like
  • justaconsumer
    , contributor
    Comments (104) | Send Message
    Stock goes sky high... And soon the world will realize that what Organovo is doing is actually nothing more than pumping premade laboratory cells through the nozzle of a printer.




    If you would have a water hose and pumped the same substance they use as ink in greater quantities through it you would more or less end up with the same useless product...


    Don't get me wrong. I certainly hope they prove me incorrect. But imo they are as far away from making a functional liver as the Chinese are from colonizing the moon and populating it with 1 million citizens...
    29 Jan, 02:08 PM Reply Like
  • ECapo
    , contributor
    Comments (434) | Send Message
    Stan The Man..great comment...all investors who followed this stock knew that they would deliver as stated..or should I say had belief in them to do so......
    I understand why shorts would keep trying to drive down this of course make more money...but why is SA authors writing a negative spin on a positive comment from ONVO??...Stan can you answer this for me!


    There has and will always be moral and ethical questions as long as science pushes for advances in the world we live in...One could argue that all satellites and shuttles should be banned for going into space...or going to the Moon or even Mars.....because this is disturbing the natural balance of things..of our atmosphere.....and the world will soon end because of this.......


    There were moral and ethical questions when heart transplants started to save human life and also when the first artificial heart were developed to keep a patient alive awaiting a transplant. Now most are asked if they want to have their drivers license endorsed as a organ donor....
    Moral about the human organ black market?


    The comment above " and whether there is a difference between this and genetically modified food crops."


    You have to be kidding is a matter of life or death for a human..not a choice on what kind of crop seed is right or wrong... or what kind of corn to eat developed with this seed or that seed ...


    Soon the shorts will jump in with this article in an attempt to drive the stock down again...for day traders so be it..but investors believed before and I imagine are having their belief in this company re affirmed now with progress being made and delivered as ONVO has stated!


    SA editors ...I wish things to be fair and balanced here....
    29 Jan, 02:34 PM Reply Like
  • J Michael McKay
    , contributor
    Comments (28) | Send Message
    It's the same thing as using news to beat the article approval process. Ask your self how Citron reports always get in on the coat tails of other negative market news. The publish articles on their site after the trend is in play and then SA accepts it as news that is influencing the main downtrend. Just in time to claim they are responsible for a market's slide. It seems to me that SA has a hole in the safety net and the mosquitos are taking advantage of it.
    30 Jan, 02:02 AM Reply Like
  • duglas
    , contributor
    Comments (12) | Send Message
    Chances of banning organ/tissue printing are zero. Further, printing of implantable organs/tissue is many years away and irrelevant to this stock today. Clearly, the article was meant to temper the upside. It worked.
    29 Jan, 02:36 PM Reply Like
  • jtm5749
    , contributor
    Comment (1) | Send Message
    Hard to hold on to this stock while Keith Murphy is selling out. Anyone know or understand why he's sold 400,000 shares over the past few months? Has he ever explained this? This gives the shorts a good reason to love it.
    29 Jan, 07:54 PM Reply Like
  • J Michael McKay
    , contributor
    Comments (28) | Send Message
    probably investing in Modern Meadows ;)
    29 Jan, 10:57 PM Reply Like
  • squashjohn
    , contributor
    Comments (28) | Send Message
    Hilarious Report, coincidentally released again when ONVO brings more positive news about their Liver development. The tentacles & reach of those with short interest is so expansive globally - a Powerful network that all investors need to be aware of..
    JTM5749: I agree - I see many trying to explain that Murphy's selling of shares is all outlined in the bonus plan for executives etc, etc.. bla bla bla.. bottom line is that he's making truck loads of cash from these sales & it doesn't inspire investor confidence in a start-up which has last qtr revenues of 23K..
    30 Jan, 04:29 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: